332 related articles for article (PubMed ID: 35131373)
1. A tabulated summary of the evidence on humoral and cellular responses to the SARS-CoV-2 Omicron VOC, as well as vaccine efficacy against this variant.
Minka SO; Minka FH
Immunol Lett; 2022 Mar; 243():38-43. PubMed ID: 35131373
[TBL] [Abstract][Full Text] [Related]
2. Humoral and Cellular Immune Responses of COVID-19 vaccines against SARS-Cov-2 Omicron variant: a systemic review.
Chen Z; Zhang Y; Wang M; Islam MS; Liao P; Hu Y; Chen X
Int J Biol Sci; 2022; 18(12):4629-4641. PubMed ID: 35874952
[TBL] [Abstract][Full Text] [Related]
3. The Vaccine Efficacy Against the SARS-CoV-2 Omicron: A Systemic Review and Meta-Analysis.
Zou Y; Huang D; Jiang Q; Guo Y; Chen C
Front Public Health; 2022; 10():940956. PubMed ID: 35910897
[TBL] [Abstract][Full Text] [Related]
4. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
5. Current evidence on efficacy of COVID-19 booster dose vaccination against the Omicron variant: A systematic review.
Chenchula S; Karunakaran P; Sharma S; Chavan M
J Med Virol; 2022 Jul; 94(7):2969-2976. PubMed ID: 35246846
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity, clinical efficacy and safety of additional second COVID-19 booster vaccines against Omicron and its subvariants: A systematic review.
Chenchula S; Chandra MB; Adusumilli MB; Ghanta SN; Bommasani A; Kuttiappan A; Padmavathi R; Amerneni KC; Chikatipalli R; Ghanta MK; Reddy SS; Mythili Bai K; Prakash S; Jogender G; Chavan M; Balakrishnan S
Rev Med Virol; 2024 Jan; 34(1):e2515. PubMed ID: 38282403
[TBL] [Abstract][Full Text] [Related]
7. Steep Decline in Binding Capability of SARS-CoV-2 Omicron Variant (B.1.1.529) RBD to the Antibodies in Early COVID-19 Convalescent Sera and Inactivated Vaccine Sera.
Zhou W; He P; Li J; Liu H; Shi M; Yu J; Wei H
Viruses; 2022 Feb; 14(2):. PubMed ID: 35215927
[TBL] [Abstract][Full Text] [Related]
8. Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination.
Silva ARD; Villas-Boas LS; Tozetto-Mendoza TR; Honorato L; Paula A; Witkin SS; Mendes-Correa MC
Rev Inst Med Trop Sao Paulo; 2022; 64():e19. PubMed ID: 35239863
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.
Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM
Elife; 2022 Jan; 11():. PubMed ID: 35072628
[TBL] [Abstract][Full Text] [Related]
10. A nasal omicron vaccine booster elicits potent neutralizing antibody response against emerging SARS-CoV-2 variants.
Lam JY; Ng YY; Yuen CK; Wong WM; Yuen KY; Kok KH
Emerg Microbes Infect; 2022 Dec; 11(1):964-967. PubMed ID: 35275039
[TBL] [Abstract][Full Text] [Related]
11. Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant.
Schubert M; Bertoglio F; Steinke S; Heine PA; Ynga-Durand MA; Maass H; Sammartino JC; Cassaniti I; Zuo F; Du L; Korn J; Milošević M; Wenzel EV; Krstanović F; Polten S; Pribanić-Matešić M; Brizić I; Baldanti F; Hammarström L; Dübel S; Šustić A; Marcotte H; Strengert M; Protić A; Piralla A; Pan-Hammarström Q; Čičin-Šain L; Hust M
BMC Med; 2022 Mar; 20(1):102. PubMed ID: 35236358
[TBL] [Abstract][Full Text] [Related]
12. Omicron (B.1.1.529) - variant of concern - molecular profile and epidemiology: a mini review.
Kannan S; Shaik Syed Ali P; Sheeza A
Eur Rev Med Pharmacol Sci; 2021 Dec; 25(24):8019-8022. PubMed ID: 34982466
[TBL] [Abstract][Full Text] [Related]
13. Humoral immune response after different SARS-CoV-2 vaccination regimens.
Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
[TBL] [Abstract][Full Text] [Related]
14. Booster BNT162b2 COVID-19 Vaccination Increases Neutralizing Antibody Titers Against the SARS-CoV-2 Omicron Variant in Both Young and Elderly Adults.
Um J; Choi YY; Kim G; Kim MK; Lee KS; Sung HK; Kim BC; Lee YK; Jang HC; Bang JH; Chung KH; Oh MD; Park JS; Jeon J
J Korean Med Sci; 2022 Mar; 37(9):e70. PubMed ID: 35257525
[TBL] [Abstract][Full Text] [Related]
15. Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days.
Gil-Manso S; Carbonell D; López-Fernández L; Miguens I; Alonso R; Buño I; Muñoz P; Ochando J; Pion M; Correa-Rocha R
Front Immunol; 2021; 12():726960. PubMed ID: 34671348
[TBL] [Abstract][Full Text] [Related]
16. Omicron variant of SARS-CoV-2 infection elicits cross-protective immunity in people who received boosters or infected with variant strains.
Chowdhury S; Chowdhury MS; Chowdhury NS; Chowdhury S; Chowdhury S
Int J Immunopathol Pharmacol; 2022; 36():3946320221133001. PubMed ID: 36214233
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the novel SARS-CoV-2 Omicron (B.1.1.529) variant of concern and its global perspective.
Saxena SK; Kumar S; Ansari S; Paweska JT; Maurya VK; Tripathi AK; Abdel-Moneim AS
J Med Virol; 2022 Apr; 94(4):1738-1744. PubMed ID: 34905235
[TBL] [Abstract][Full Text] [Related]
18. Three doses of an inactivation-based COVID-19 vaccine induces cross-neutralizing immunity against the SARS CoV-2 Omicron variant.
Yu X; Qi X; Cao Y; Li P; Lu L; Wang P; Feng Y; Yang J; Wei H; Guo L; Sun M; Liu Q; Lv J; Feng Y
Emerg Microbes Infect; 2022 Dec; 11(1):749-752. PubMed ID: 35176972
[TBL] [Abstract][Full Text] [Related]
19. B and T cell response to SARS-CoV-2 vaccination in health care professionals with and without previous COVID-19.
Zollner A; Watschinger C; Rössler A; Farcet MR; Penner A; Böhm V; Kiechl SJ; Stampfel G; Hintenberger R; Tilg H; Koch R; Antlanger M; Kreil TR; Kimpel J; Moschen AR
EBioMedicine; 2021 Aug; 70():103539. PubMed ID: 34391087
[TBL] [Abstract][Full Text] [Related]
20. Omicron: Call for updated vaccines.
Li X
J Med Virol; 2022 Apr; 94(4):1261-1263. PubMed ID: 34927258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
